|Bid||30.48 x 900|
|Ask||54.89 x 800|
|Day's range||47.26 - 48.75|
|52-week range||32.47 - 62.16|
|Beta (5Y monthly)||1.56|
|PE ratio (TTM)||2.05|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Agios (AGIO) is seeking approval for its lead pipeline candidate, mitapivat, as a potential treatment for PK deficiency.
Agios Pharmaceuticals (AGIO) reports narrowed-than-expected loss for the second quarter of 2021. The company did not record any revenue following the oncology portfolio sale.
AGIO earnings call for the period ending June 30, 2021.